Exelixis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.10.24	Exelixis, Merck Sign Clinical Development Deal To Evaluate Zanzalintinib With KEYTRUDA, WELIREG (RTTNews)
18.09.24	SLNO Skyrockets 800%, BWAY Blasts Past 400% - Were You On Board? (RTTNews)
16.09.24	Exelixis Phase 3 CABINET Study Of Cabozantinib In Tumors Results In Progression Free Survival (RTTNews)
06.08.24	Exelixis: FDA To Review Supplemental New Drug Application For Cabozantinib (RTTNews)
02.07.24	Ipsen Expands Exelixis Collaboration For Cabometyx In Advanced Neuroendocrine Tumors (RTTNews)
20.05.24	Exelixis Resolves Two CABOMETYX Patent Disputes With Cipla (RTTNews)
08.01.24	Exelixis To Cut 13% Of Jobs, Repurchase Up To Addl $450 Mln Of Shares; Sees FY Revenues Below View (RTTNews)
04.12.23	Exelixis, Arcus Biosciences Enter Clinical Trial Collaboration - Quick Facts (RTTNews)
10.11.23	Exelixis Announces Encouraging Results From Phase 1b Trial Of Zanzalintinib In Kidney Cancer (RTTNews)
12.09.23	Insilico Grants Exelixis Worldwide License To Develop, Commercialize ISM3091 (RTTNews)
24.08.23	Exelixis Announces Positive Results From Phase 3 Trial Of Cabozantinib In Advanced Pancreatic (RTTNews)
21.08.23	Exelixis, Ipsen Reports Positive Phase 3 CONTACT-02 Study Data In Prostate Cancer (RTTNews)
20.03.23	Exelixis Board Authorizes Repurchase Of Common Stock - Quick Facts (RTTNews)
07.02.23	Exelixis, Inc. Q4 Earnings Summary (RTTNews)
04.10.22	Exelixis Expands Agreement With Bristol Myers For STELLAR-002 Trial - Quick Facts (RTTNews)
14.10.21	Exelixis, STORM Collaborate To Discover And Advance Novel Drug Leads Intended For Cancer Treatment (RTTNews)
18.09.21	Exelixis Presents Results Of Cabozantinib On Metastatic Castration-Resistant Prostate Cancer (RTTNews)
18.09.21	FDA Approves Exelixis' Cabometyx To Treat Metastatic Differentiated Thyroid Cancer (RTTNews)
16.09.21	Exelixis Reports Positive Data From Post-hoc Exploratory Analysis Of Phase 3 CheckMate -9ER Trial (RTTNews)
07.09.21	Exelixis Says Two Senior Executives Passed Away (RTTNews)
16.08.21	Exelixis, Invenra Announce Expanded Collaboration - Quick Facts (RTTNews)
14.06.21	Exelixis, Bristol Myers To Evaluate XL092-Immuno-oncology Therapies In Advanced Solid Tumors (RTTNews)
05.04.21	Exelixis Says FDA Accepts IND For XB002 In Patients With Advanced Solid Tumors - Quick Facts (RTTNews)
27.11.20	Exelixis Says Takeda Receives Approval For Cabometyx In Japan - Quick Facts (RTTNews)
10.07.20	Stock Alert: Exelixis Up 4% (RTTNews)
21.04.20	CYCC In STOPCOVID, EXEL Hits New High, NVS Trialing Malaria Drug For COVID-19 (RTTNews)
20.04.20	Stock Alert: Exelixis Stock Up 19% In Premarket (RTTNews)
25.03.20	Stock Alert: Exelixis Shares Up 13% In Pre-Market (RTTNews)
05.02.20	Stock Alert: Exelixis On The Move (RTTNews)
01.08.19	AMRN'S Vascepa Hits Record Sales, ADMP Slumps On Stock Offering, SRDX On Watch… (RTTNews)
15.01.19	First Device For Congenital Heart Defect, AIMT & US Shutdown, ASLN On Watch (RTTNews)
11.01.19	9 Pharma Stocks To Watch This Month (RTTNews)
24.12.18	Biotech Stocks Facing FDA Decision In January 2019 (RTTNews)
26.06.18	Copart To Replace Dr Pepper Snapple Group In S&P 500 (RTTNews)
30.05.18	AKER Withdraws 510(K), TTOO Turns Head, CPRX, LOXO To Face FDA In Nov. (RTTNews)
17.05.18	Exelixis To Get $50 Mln As Ipsen Gets Expanded EC Approval For CABOMETYX (RTTNews)
14.02.18	TTPH Implodes On IGNITE3, EC Approves 2nd Herceptin Biosimilar, PTIE At It Again (RTTNews)
17.01.18	EIGR Disappoints, EXEL's CELESTIAL Excels, JUNO In CELG's Crosshairs? (RTTNews)
20.12.17	EXEL, PFE, ONCE Get FDA Nod, FPRX, ZLAB Team Up, SKLN Soars After Hours (RTTNews)
22.11.17	First 2-drug HIV Regimen Gets FDA Nod, Starpharma Shines, ARDX Drops RDX7675 (RTTNews)
02.11.17	NBIX Delivers, MNTA's Biosimilar Drug Trial Fails, No FDA Panel Meet For RARE (RTTNews)
17.10.17	HIIQ In Good Health, BOLD Awaits ASPIRO Data, CELESTIAL Lights Up EXEL (RTTNews)
16.10.17	Exelixis Remains Sharply Higher After Early Rally (RTTNews)
16.10.17	Exelixis' Cabozantinib: Trial In HCC Meets Main Goal; FDA Priority Review In RCC (RTTNews)
16.10.17	Ipsen : Phase 3 CELESTIAL Trial Of Cabozantinib Meets Primary Endpoint In HCC (RTTNews)
25.09.17	Opdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches Eyes (RTTNews)
11.09.17	New Hope For AZN's Old Drug, More About BMY's Opdivo, IMDZ On Watch (RTTNews)
08.09.17	NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted (RTTNews)
28.08.17	Stock Performance Review on Biotech Industry -- Exelixis, Geron, Inovio Pharma, and Intra Cellular Therapies (PR Newswire)
24.07.17	Technical Snapshots for These Biotech Stocks -- Exelixis, Celldex Therapeutics, Clovis Oncology, and Geron (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

30.10.24		Anleger in New York halten sich zurück: NASDAQ Composite gibt zum Handelsende nach
30.10.24		Handel in New York: NASDAQ Composite verbucht Verluste
30.10.24		Gute Stimmung in New York: NASDAQ Composite mittags fester
30.10.24		Mittwochshandel in New York: NASDAQ Composite beginnt Mittwochssitzung in der Gewinnzone
15.10.24		Schwacher Handel in New York: NASDAQ Composite legt schlussendlich den Rückwärtsgang ein
15.10.24		Schwacher Handel: NASDAQ Composite zeigt sich leichter
15.10.24		Dienstagshandel in New York: NASDAQ Composite gibt nach
18.09.24		Angespannte Stimmung in New York: NASDAQ Composite präsentiert sich mittags schwächer

30.10.24

Anleger in New York halten sich zurück: NASDAQ Composite gibt zum Handelsende nach

30.10.24

Handel in New York: NASDAQ Composite verbucht Verluste

30.10.24

Gute Stimmung in New York: NASDAQ Composite mittags fester

30.10.24

Mittwochshandel in New York: NASDAQ Composite beginnt Mittwochssitzung in der Gewinnzone

15.10.24

Schwacher Handel in New York: NASDAQ Composite legt schlussendlich den Rückwärtsgang ein

15.10.24

Schwacher Handel: NASDAQ Composite zeigt sich leichter